Please assess the completion status of the following clinical trial:

Trial Title: A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients must have previously untreated MDS, AML, or CMML according to the WHO 2016 classification.~* MDS patients must have Intermediate (\>3 to 4.5 points), High Risk (\>4.5 - 6) or Very High Risk (\>6 points) disease according to the Revised International Prognostic Scoring System 2012 (IPSS-R).~* Clinical indication for treatment with azacitidine for MDS or AML.~Exclusion criteria:~* Patients with AML who are candidates for standard induction chemotherapy as first line treatment.~* Patients with known active CNS leukemia.~* Prior treatment with a smoothened inhibitor (SMOi) and/or hypomethylating agent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): MDS patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
- Arm B (Type: EXPERIMENTAL): AML patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).